TrialJectory seals $2.7 mln seed
New York City-based TrialJectory, an AI-powered technology platform that uses self-reported clinical data to match cancer patients with clinical trials, has secured $2.7 million in seed financing.
New York City-based TrialJectory, an AI-powered technology platform that uses self-reported clinical data to match cancer patients with clinical trials, has secured $2.7 million in seed financing.
Copyright PEI Media
Not for publication, email or dissemination